Ephicacy

Ephicacy was formed in 2005 in New Jersey, US, with an objective of being a niche provider of data analytics services in supporting research and clinical trial activities in life sciences industry. Technology services in healthcare analytics is also an integral part of our offerings. Ephicacy’s presence in Bangalore, India was established in 2009. Established as a Centre of Excellence (CoE), the intent is to tap locally available talent and serve the needs of customers worldwide. Our focus on hiring and nurturing talent through well-established learning and development processes have led to the creation of a competent and committed team. The COE in India is delivery driven with well-documented and practised SOPs. We are also certified ISO 9001:2015 and an ISO 27001:2013 company. Our global delivery organization comprises of a well-knit team of experienced biostatisticians, clinical programmers, data managers, and domain experts to meet the ever-growing needs of clinical analytics leaders. Our technology service includes expertise in product design, web-based and cloud technologies with special interest in healthcare domain. Ephicacy has stepped up to address the paucity of qualified resources in these functional areas and is able to rapidly fulfil the needs of customers using flexible and bespoke business engagement models. Our highly qualified leadership team handpicks resources from our pool of qualified professionals to ensure customer projects are well resourced. Today, Ephicacy has proven to be a pioneer and continues to be a forerunner in providing ACCURATE, ON TIME AND SECURE solutions for pharmaceuticals, biotechnology, medical research, and healthcare organizations worldwide.

MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating. For more information, visit www.mmsholdings.com

CAI

Fundamentally we exist for one reason: To be the trusted solution for our clients as they strive to build a better working world and improve the human experience. To us, this means we provide engineers, project managers, scientists, and technicians to efficiently startup, document the process, train the operators, lower cost of goods, and drive speed to patient. We are 800+ global experts that bring top-tier expertise to every stage of a project, from creating comprehensive, detailed project plans to eliminating that last punch list item and beyond, into rigorous asset management, reliability, and sustainability activities. We are your choice regardless of your location. Philosophically and practically, we believe that quality, cost, and schedule can be mutually reinforcing – trade-offs are not necessary. Short-changing the focus on quality usually means problems down the road – problems that can cost money and delay the schedule. But if quality is built in from the start, then both project delivery and operational efficiency can be achieved with a much higher degree of assurance. When your project requires planned, managed, and documented high quality to exacting global standards. When you need high-performance teams on mission-critical projects. When your project is complex, high-visibility, and carries significant risk. We can help you meet a higher standard.

Shionogi Inc. (U.S.)

Since 1878, we have been committed to developing new treatments to improve patients' lives worldwide. We are helping to address global health challenges such as antimicrobial resistance and COVID-19. Since the 1950s, we have discovered and introduced several novel antibiotics, as well as innovative medications for HIV and influenza. Today, we are developing an investigational oral antiviral for COVID-19 and advancing clinical programs in Fragile X syndrome, acute ischemic stroke as well metabolic disorders and oncology. Our team is driven to impact patient lives. Our partnerships with industry, government agencies, biotech companies and academia help to advance science with the urgency that today's health challenges demand. Through a combination of in-house discovery and strategic partnerships, we continue to deliver firsts for patients in the U.S. and worldwide.

pdi, inc.

PDI is a leading healthcare commercialization company providing superior insight-driven, integrated multi-channel message delivery for established and emerging healthcare companies. The company is dedicated to: -Providing outsourced sales and marketing expertise -Creating innovative digital and multi-channel promotional solutions -Enhancing engagement with health care practitioners -Optimizing clients’ commercial investments -Providing clients with strategic flexibility -Delivering full product commercialization services Founded in 1988, PDI was one of the first contract sales organizations (CSOs) in the United States. Today, PDI is reshaping the way pharmaceutical, biotech, medical device, and diagnostics companies reach and engage customers, commercialize products, and manage their portfolios.